Previous 10 | Next 10 |
2023-08-31 09:43:19 ET Summary Vertex Pharmaceuticals has performed well since my previous update due to the continued strength of the commercial cystic fibrosis business. The focus will soon shift to late-stage pipeline assets, primarily gene editing candidate exa-cel and pain ca...
ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a...
2023-08-28 22:29:27 ET Summary CRISPR Therapeutics is collaborating with Vertex on exa-cel, a therapy using CRISPR gene-editing, for severe sickle cell disease and transfusion-dependent beta thalassemia. Regulatory bodies are evaluating the potential approval of exa-cel, but compe...
2023-08-24 15:42:35 ET More on bluebird bio, CRISPR, etc. Vertex Pharmaceuticals Still Looks Attractive Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans Vertex Pharmaceuticals: Strategically Positioning For Future Success Vertex And C...
2023-08-22 08:20:00 ET Summary Vertex Pharmaceuticals, CRISPR Therapeutics and bluebird bio are penning a new chapter in the story of gene therapy for sickle cell disease. The Institute for Clinical and Economic Review (ICER) has recently released a report about exagamglogene auto...
2023-08-21 11:56:10 ET More on gene therapies Vertex Pharmaceuticals: Strategically Positioning For Future Success Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued Crispr Therapeutics: Biotech To Watch With Regulatory Approvals Of Exa-Cel O...
2023-08-17 15:16:43 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued Crispr Therapeutics: Biotech To Watch With Regulatory Approvals Of Exa-Cel On Deck Crispr Therapeutics Has Value Creation Potential ...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
2023-08-14 06:15:00 ET The market experienced a wild ride in 2022, making investors hesitant to invest in the stock market. However, the S&P 500 appears to have turned the corner this year, rising 17% so far. In this recovering market, growth stocks that are still undervalued ...
2023-08-12 07:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is one of the most innovative biotechs out there, and that means there's no shortage of reasons to consider buying its stock. But much like its peers, it's a high-risk investment until it gets its first medicine out the door ...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: